NOV 13, 2013
The proprietary lab test combines traditional markers with three novel, proprietary biomarkers, allowing earlier detection of the disease, according Nicox. The company’s sales force is now promoting the test, called Sjö, to eye care professionals in select US markets.
Nicox also announced a partnership with the Sjögren’s Syndrome Foundation to raise awareness of the disease among eye care professionals.
“The launch of a proprietary, novel test for early detection of Sjögren’s Syndrome demonstrates the potential of ophthalmic diagnostics in a wide range of conditions,” said Jerry St. Peter, executive vice president and general manager of Nicox. “Sjö is the second diagnostic which Nicox has launched in the US and represents another important step towards our goal of becoming a leading provider of ophthalmic diagnostics, drugs and devices.”